United Pharm (033270.KS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · South Korea · ISIN KR7033270000
United Pharm financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 288.71 bn KRW | 288.76 bn KRW |
| Gross profit | 163.97 bn KRW | 160.60 bn KRW |
| Operating income | 33.52 bn KRW | 50.11 bn KRW |
| EBIT | 46.57 bn KRW | 50.00 bn KRW |
| Net income | 32.45 bn KRW | 38.31 bn KRW |
| Diluted EPS – continuing operations | 2,206.00 KRW | 2,652.61 KRW |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About United Pharm
Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to approximately 40 countries. Korea United Pharm Inc. was founded in 1987 and is headquartered in Seoul, South Korea.
More stocks
- Deezer S.A. (DEEZR.PA)
- AirJoule Technologies Corp. (AIRJ)
- Fiera Capital Corporation (FSZ.TO)
- Niagen Bioscience, Inc. (NAGE)
- NRC Group ASA (NRC.OL)
- Fidelix Co. Ltd (032580.KQ)
- VINCE HOLDING CORP. (VNCE)
- Donga Geologic (028100.KS)
- OptimizeRx Corp (OPRX)
- AN2 Therapeutics, Inc. (ANTX)
- Pappajack Bhd (0242.KL)
- Umweltbank (UBK.DE)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.